Johnson & Johnson $JNJ Shares Bought by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. grew its stake in Johnson & Johnson (NYSE:JNJ) by 9.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 432,376 shares of the company’s stock after purchasing an additional 38,570 shares during the quarter. Johnson & Johnson comprises about 0.3% of Rakuten Investment Management Inc.’s holdings, making the stock its 28th biggest holding. Rakuten Investment Management Inc.’s holdings in Johnson & Johnson were worth $115,691,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. Westhampton Capital LLC lifted its position in Johnson & Johnson by 1.7% during the third quarter. Westhampton Capital LLC now owns 12,984 shares of the company’s stock valued at $3,437,000 after buying an additional 216 shares during the period. MFG Investments LLC purchased a new stake in shares of Johnson & Johnson in the 3rd quarter worth about $422,000. Third View Private Wealth LLC grew its position in shares of Johnson & Johnson by 4.7% in the 3rd quarter. Third View Private Wealth LLC now owns 18,215 shares of the company’s stock worth $4,822,000 after buying an additional 811 shares during the period. Provenance Wealth Advisors LLC increased its stake in shares of Johnson & Johnson by 214.5% in the 3rd quarter. Provenance Wealth Advisors LLC now owns 15,890 shares of the company’s stock worth $4,207,000 after acquiring an additional 10,838 shares in the last quarter. Finally, One Day In July LLC increased its stake in shares of Johnson & Johnson by 2.6% in the 3rd quarter. One Day In July LLC now owns 3,925 shares of the company’s stock worth $1,039,000 after acquiring an additional 100 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 3.9%

Johnson & Johnson stock opened at $276.62 on Thursday. The firm has a market cap of $665.92 billion, a price-to-earnings ratio of 41.91, a PEG ratio of 2.63 and a beta of 0.22. The stock has a fifty day simple moving average of $265.67 and a two-hundred day simple moving average of $247.74. Johnson & Johnson has a 12 month low of $185.12 and a 12 month high of $282.02. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. During the same period last year, the firm posted $2.80 earnings per share. Johnson & Johnson’s revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities analysts predict that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. Johnson & Johnson’s dividend payout ratio is 81.21%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on JNJ. Wells Fargo & Company upped their price objective on shares of Johnson & Johnson from $275.00 to $287.00 and gave the stock an “overweight” rating in a report on Friday, October 16th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $282.00 target price on shares of Johnson & Johnson in a research note on Thursday, July 16th. Bank of America reiterated a “neutral” rating and set a $278.00 target price on shares of Johnson & Johnson in a report on Tuesday, September 29th. TD Cowen reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 20th. Finally, Weiss Ratings downgraded Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a research note on Friday, October 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $275.92.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Wall Street analysts remain moderately bullish on J&J’s prospects, according to a review of analyst views. Read article
• Neutral Sentiment: State Street’s Health Care SPDR added J&J shares as part of a $175.3 million purchase that increased all 60 of the fund’s holdings. This indicates fund buying, but the report does not specify J&J’s allocation or suggest a company-specific investment view. Read article
• Neutral Sentiment: Smith+Nephew cut its outlook and confirmed failed merger discussions with J&J’s orthopedics unit. The talks’ failure removes a potential transaction, but the report does not detail any direct financial impact on J&J. Read article
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of J&J investors. The announcement could create negative legal overhang, although it does not provide details about the claims or establish wrongdoing. Read article

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jennifer Taubert sold 15,000 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.